Oslo, Norway, March 1, 2023: Reference is made to Targovax ASA’s (“Targovax” or the “Company”) stock exchange announcement dated February 16, 2023, in which the Company will convene an Extraordinary General Meeting (EGM) at the Company’s offices raised at Lysaker on 9 March 2023 at 10:00 CET for the purpose of approving the investment agreement for up to NOK 300 million in convertible bonds with Atlas Special Opportunities, LLC (“Atlas”).
Material and relevant portions of the Atlas Investment and Subscription Agreement have been published on the Company’s website: https://www.targovax.com/en/extraordinary-general-meeting-2023/ and are also attached to this notice.
On February 28, 2023, a webcast presentation with questions and answers on Atlas’ convertible bond was held. A recording of the presentation and the presentation material are available on our website at the following link: https://www.targovax.com/en/presentations/.
Appendix: Atlas Investment Agreement Public Terms
***
For more information please contact:
Erik Digman Wiklund, CEO
Telephone: +47 413 33 536
Email: [email protected]
Renate Birkeli, Investor Relations
Telephone: +47 922 61 624
Email: [email protected]
Media Inquiries:
Andreas Tinglum – Corporate Communications (Norway)
Telephone: +47 9300 1773
Email: [email protected]
About Targovax
Activation of the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical-stage immuno-oncology company developing immune activators that target hard-to-treat solid tumors. Targovax is focused on activating the patient’s immune system to fight cancer and helping cancer patients with few treatment alternatives available. Targovax is developing its product candidates in multiple cancer indications, including melanoma, mesothelioma, multiple myeloma and pancreatic cancer.
Targovax’s lead clinical candidate, ONCOS-102, is a genetically engineered oncolytic adenovirus designed to selectively infect cancer cells and activate the immune system against the tumor. ONCOS-102 has demonstrated a favorable efficacy, immune and safety profile in multiple indications, both as monotherapy and in combination, and ONCOS-102 is in a randomized Phase 2 study in melanoma patients refractory to treatment with PD -1 checkpoint inhibitors are resistant.
Targovax has also established a state-of-the-art circular RNA program (circRNA) with the intent to develop next-generation RNA therapeutics for various applications, building on clinical experience and deep mechanistic insights from its first-generation products. In addition, Targovax has a KRAS immunotherapy program with lead candidate TG01 set to enter clinical trials in early 2023 in an expanded format in pancreatic cancer and multiple myeloma. This provides Targovax with a rich pipeline of innovative future therapeutic candidates to follow ONCOS-102.
https://news.cision.com/targovax/r/targovax-asa—additional-information-before-extraordinary-general-meeting,c3725461
https://mb.cision.com/Public/17093/3725461/9751250818e84b14.pdf
(c) Decision 2023. All rights reserved., Source press releases – English
